<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-0099</journal-id>
<journal-title><![CDATA[Cirujano general]]></journal-title>
<abbrev-journal-title><![CDATA[Cir. gen]]></abbrev-journal-title>
<issn>1405-0099</issn>
<publisher>
<publisher-name><![CDATA[Asociación Mexicana de Cirugía General A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-00992014000100033</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Manejo de fístula pancreática posquirúrgica con un análogo de somatostatina (octreótido LAR)]]></article-title>
<article-title xml:lang="en"><![CDATA[Management of post-surgical pancreatic fistulae with a somatostatin analogue (Octreotide LAR®)]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez González]]></surname>
<given-names><![CDATA[Luis Ricardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hermosillo Sandoval]]></surname>
<given-names><![CDATA[José Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arellano Martínez]]></surname>
<given-names><![CDATA[Ruth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Andrade Ortega]]></surname>
<given-names><![CDATA[Carlos Adolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montes Velázquez]]></surname>
<given-names><![CDATA[Leonora]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lomelí Muñoz]]></surname>
<given-names><![CDATA[Jorge Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social  ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social  ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2014</year>
</pub-date>
<volume>36</volume>
<numero>1</numero>
<fpage>33</fpage>
<lpage>38</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-00992014000100033&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-00992014000100033&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-00992014000100033&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  La prevalencia de fístula pancreática posterior a patología inflamatoria, neoplásica o traumática aun representa un problema en cirugía. El propósito de este estudio fue identificar la utilidad de un análogo de la somatostatina en el cierre de la fístula pancreática.  Material y métodos:  En esta cohorte retrospectiva evaluamos a 11 pacientes operados por patología pancreática de origen neoplásico, inflamatorio o traumático, en los últimos 18 meses y que desarrollaron fístula pancreática como complicación quirúrgica. Todos los casos fueron manejados con octreótido long acting release (LAR) (Novartis International AG, Basel, Suiza) a dosis de 20 mg por vía intramuscular. Evaluamos: tiempo de cierre de la fístula, estancia intrahospitalaria, clasificación de la fístula por gasto, operación realizada y tipo de cirugía.  Resultados:  El rango de edad fue de 16 a 72 años (media 38 años). De los 11 pacientes evaluados, 7 (63%) lograron un cierre de trayecto fistuloso en un rango de 7 a 22 días con una sola dosis de octreótido LAR®, 3 (27,3%) casos necesitaron 2 dosis de octreótido LAR y obteniendo un cierre en rango de entre 45 a 53 días; solamente un (9,1%) paciente requirió 3 dosis, registrando un cierre a los 73 días de haberse documentado la fístula pancreática.  Conclusión:  El análogo de somatostatina (octreótido LAR) es una buena alternativa terapéutica en el manejo de fístula pancreática a dosis de 20 mg aplicado por vía intramuscular y demostrando acortamiento en el tiempo de cierre y estancia intrahospitalaria.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  The prevalence of pancreatic fistulae after inflammatory, neoplastic, and traumatic disorders still represents a problem in surgery. The present study was aimed at assessing the usefulness of a somatostatin analog for pancreatic fistula closure.  Material and methods:  Eleven patients who were operated on for neoplastic, infl ammatory o traumatic disorders in the last 18 months and developed pancreatic fistulae as a surgical complication were included in this retrospective cohort study. All patients were managed with Octreotide LAR® (Novartis International AG, Basel, Switzerland) 20 mg intramuscularly. The following endpoints were assessed: time to fistula closure, hospital stay duration, classification of fistula based on output, and type of surgery.  Results:  Age range was 16 to 72 years (mean, 38 years). Out of 11 evaluated patients, 7 (63%) achieved closure of fi stula tract within 7-22 days with a single dose of octreotide LAR®, three (27.3%) patients required 2 doses of octreotide and achieved closure within 45-53 days. Only one patient (9.1%) required 3 somatostatin doses, with closure being documented 73 days after fistula diagnosis.  Conclusion:  A somatostatin analogue (Octreotide LAR®) is a good therapeutic alternative in the management of pancreatic fi stulae when prescribed at doses of 20 mg intramuscularly, and results in closure time shortening and a shorter hospital stay.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Fístula pancreática]]></kwd>
<kwd lng="es"><![CDATA[Cirugía]]></kwd>
<kwd lng="es"><![CDATA[Octreótido LAR]]></kwd>
<kwd lng="en"><![CDATA[Pancreatic fistula]]></kwd>
<kwd lng="en"><![CDATA[Surgery]]></kwd>
<kwd lng="en"><![CDATA[Octreotide LAR®]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brunicardi]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Billiar]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Páncreas]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Schwartz]]></surname>
</name>
</person-group>
<source><![CDATA[Principios de cirugía]]></source>
<year>2010</year>
<volume>2</volume>
<edition>9</edition>
<page-range>1003-123</page-range><publisher-name><![CDATA[Mc Graw Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steer]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Páncreas exocrino]]></article-title>
<source><![CDATA[Sabiston: textbook of surgery. The biological basis of modern surgical practice]]></source>
<year>2007</year>
<edition>18</edition>
<page-range>1254-89</page-range><publisher-name><![CDATA[Saunders Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lansden]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of external pancreatic fistulas with somatostatin]]></article-title>
<source><![CDATA[Am Surg]]></source>
<year>1989</year>
<volume>55</volume>
<page-range>695-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carballo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Calvet]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Pancorbo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[De la Morena]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is somatostatin useful in the treatment of acute pancreatitis A metaanalysis]]></article-title>
<source><![CDATA[Digestion]]></source>
<year>1991</year>
<volume>49</volume>
<page-range>12-3</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harwood]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Girotti]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Octreotide acetate to treat pancreatid fistula]]></article-title>
<source><![CDATA[Can J Hosp Pharm]]></source>
<year>1992</year>
<volume>45</volume>
<page-range>248-50</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prinz]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Pickleman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of pancreatic cutaneous fistulas with a somatostatin analog]]></article-title>
<source><![CDATA[Am J Surg]]></source>
<year>1988</year>
<volume>155</volume>
<page-range>36-42</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Goodgame]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pancreatic resection in man effect of fasting, drugs, pancreatic enzymes, and somatostatin]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>1994</year>
<volume>89</volume>
<page-range>267-70</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schroder]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kivilaakso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kalima]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lempinen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of pancreatic fi stulas with somatostatin and total parenteral nutrition]]></article-title>
<source><![CDATA[Scand J Gastroenterol]]></source>
<year>1989</year>
<volume>24</volume>
<page-range>859-62</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yeo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cameron]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Lillemoe]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Sauter]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Coleman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sohn]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy Results of a prospective randomized placebo-controlled trial]]></article-title>
<source><![CDATA[Ann Surg]]></source>
<year>2000</year>
<volume>232</volume>
<page-range>419-29</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lowy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Pisters]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Fenoglio]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stanford]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective randomized trial of ocreotide to prevent pancreatic fistula pancreaticoduodenectomy for malignant disease]]></article-title>
<source><![CDATA[Amm Surg]]></source>
<year>1997</year>
<volume>226</volume>
<page-range>632-41</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Avgerinos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Armonis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Raptis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Somatostatin and octreotide in the management of acute variceal bleeding]]></article-title>
<source><![CDATA[Hepato-Gastroenterology]]></source>
<year>1995</year>
<volume>42</volume>
<page-range>145-50</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montorsi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zago]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mosca]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Capussotti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zotti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ribotta]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effi cacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections a prospective, controlled,randomized clinical trial]]></article-title>
<source><![CDATA[Surgery]]></source>
<year>1995</year>
<volume>117</volume>
<page-range>26-31</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nubiola-Calonge]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Badia]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Sancho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sitges-Serra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1987</year>
<volume>2</volume>
<page-range>672-3</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stolk]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[van Erpecum]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Koppeschaar]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Samson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Smount]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Akkermans]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Van Berge-Henegouwen]]></article-title>
<source><![CDATA[Gut]]></source>
<year>1995</year>
<volume>36</volume>
<page-range>755-60</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maes]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Ghoss]]></surname>
<given-names><![CDATA[YF]]></given-names>
</name>
<name>
<surname><![CDATA[Geypens]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hiele]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Rutgeers]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of octreotide on the gastric emptying of solids and liquids in normal healthy subjects]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>1995</year>
<volume>9</volume>
<page-range>11-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
